Preparation method of ceritinib and intermediate

A technology of ceritinib and intermediates, which is applied in the field of preparation of ceritinib and its intermediates, can solve the problems of increased side reactions, cumbersome operations, and reduced total yield, and achieves mild conditions, simple processes, and side effects. Response reduction effect

Active Publication Date: 2014-08-20
SCI GENERAL MATERIAL & CHEM
View PDF6 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Investigate this method, because the three chlorine atoms in the starting material 2,4,5-trichloropyrimidine (IX) have limited selectivity differences when nucleophilic substitution reactions occur, there are multiple competitive reactions, which increase side reactions
In the actual operation process, in order to reduce side reactions, the piperidine ring in the raw materi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of ceritinib and intermediate
  • Preparation method of ceritinib and intermediate
  • Preparation method of ceritinib and intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Add 4-(5-isopropoxy-2-methyl-4-nitrophenyl)pyridine (II) (2.72g, 10mmol) and 10% palladium carbon (0.27g, 10%w / w), 25mL saturated hydrogen chloride isopropanol solution and 100mL isopropanol, according to the hydrogenation reaction operation procedure, feed hydrogen, keep at 50-60°C, 8-10Kg / em 2 The reaction was stirred for 16 hours until hydrogen was no longer consumed. Cool, filter and recover palladium carbon, concentrate under reduced pressure to recover the solvent, dissolve the residue with dichloromethane and wash with saturated sodium bicarbonate, separate the organic phase, concentrate under reduced pressure, and the obtained crude product is washed with ethyl acetate and n-hexane (1:1) Recrystallization gave 2.27 g of off-white solid 2-isopropoxy-5-methyl-4-(piperidin-4-yl)aniline (III), with a yield of 91.5%.

Embodiment 2

[0032] Add 4-(5-isopropoxy-2-methyl-4-nitrophenyl)pyridine (II) (2.72g, 10mmol), Raney nickel (0.54g), 0.1mL concentrated Sulfuric acid and 120mL isopropanol, according to the hydrogenation reaction operating procedure, pass in hydrogen, keep at 40-50°C, 5-8Kg / cm 2 The reaction was stirred for 22 hours until hydrogen was no longer consumed. Cool, filter to recover the catalyst, concentrate under reduced pressure to recover the solvent, dissolve the residue with dichloromethane and wash with saturated sodium bicarbonate, separate the organic phase, concentrate under reduced pressure, and weigh the obtained crude product with ethyl acetate and n-hexane (1:1). Crystallized to obtain 2.21 g of off-white solid 2-isopropoxy-5-methyl-4-(piperidin-4-yl)aniline (III), with a yield of 89.1%.

Embodiment 3

[0034]Add 2-isopropoxy-5-methyl-4-(piperidin-4-yl)aniline (III) (2.48g, 10mmol), 5mL of 40% hydrobromic acid solution and 20mL of water into the three-necked flask, keep At 0-5°C, a 20 mL aqueous solution of sodium nitrite (1.38 g, 20 mmol) was added dropwise, and the reaction was continued for 2 hours after the drop was completed. Add cuprous bromide (1.57g, 11mmol), heat up to 50-60°C, react for 2 hours, cool, filter to remove solids, extract the mother liquor 3 times with dichloromethane, combine the organic phases, and successively wash with saturated sodium bicarbonate solution Wash with saturated brine, dry over anhydrous sodium sulfate, recover the solvent under reduced pressure, and the resulting oil is 2-isopropoxy-5-methyl-4-(piperidin-4-yl)bromobenzene (I) 2.58g , yield 83.0%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an intermediate 2-isopropoxy-5-methyl-4-(piperidyl-4-yl)halogeno-benzene (I) for preparing ceritinib and a preparation method thereof. The preparation method comprises the following steps: carrying out catalytic hydrogenation on the raw material 4-(5-isopropoxy-2-methyl-4-nitrophenyl)pyridine (II) to obtain 2-isopropoxy-5-methyl-4-(piperidyl-4-yl)aniline (III); and carrying out Sandmeyer reaction on the compound (III) to obtain the 2-isopropoxy-5-methyl-4-(piperidyl-4-yl)halogeno-benzene (I). The invention also discloses a preparation method of ceritinib. The 2-isopropoxy-5-methyl-4-(piperidyl-4-yl)halogeno-benzene (I) used as the raw material is sequentially subjected to substitution, reduction and substitution reaction to obtain the ceritinib (VIII). The preparation method has the advantages of simple technique, mild conditions and fewer side reactions, and is suitable for industrial amplification.

Description

technical field [0001] The invention belongs to the technical field of organic synthesis route design and preparation of raw materials and intermediates, and in particular relates to a preparation method of Ceritinib and intermediates thereof. Background technique [0002] Ceritinib (formerly known as LDK378) is an anaplastic lymphoma enzyme (ALK) tyrosine kinase inhibitor developed by Novartis. The treatment of patients with metastatic NSCLC whose disease has progressed or cannot be tolerated after Crizotinib treatment, the trade name is Zykadia. Since the drug has not been officially marketed in my country and does not have a standard Chinese translation, the applicant hereby transliterates it as "ceritinib". Ceritinib is the second ALK inhibitor approved by the FDA after Crizotinib, and also the second drug to be marketed through the quadruple special approval channel after Ibrutinib. [0003] Ceritinib (Ceritinib, VIII), the chemical name is 5-chloro-N 2 -[2-Isopropox...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D211/22C07D401/12
CPCC07D211/22C07D401/12
Inventor 许学农
Owner SCI GENERAL MATERIAL & CHEM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap